Latest Breaking News On - Transcatheter cardiovascular therapeutics - Page 6 : comparemela.com

Recor Medical claims first FDA approval in renal denervation for stubbornly high blood pressure

Recor Medical claims first FDA approval in renal denervation for stubbornly high blood pressure
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesLara barghoutSymplicity spyralRecor medicalTokyo based otsukaTranscatheter cardiovascular therapeutics

Xenter Unveils Groundbreaking Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023

Xenter Unveils Groundbreaking Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023
venturebeat.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from venturebeat.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSalt lake citySan franciscoWilliama grayMike russellInterventionalcardiology digitalhealthBryan osbornXenter incCatheterization labCardiovascular research foundationRevolutionizing data collectionProprietary wirelessTranscatheter cardiovascular therapeuticsBusiness wireArtificial intelligence

Shockwave Medical Reports Third Quarter 2023 Financial Results

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercializatio.

United kingdomUnited statesDoug godshallScott shadiowDebbie kasterExchange commissionCardiovascular research foundationUs centers for medicare medicaid servicesShockwave medical incEuropean unionCoronary intravascular lithotripsyTranscatheter cardiovascular therapeuticsCardiovascular researchCategoryi current procedural terminologyIntravascular lithotripsyMedicaid services

Drug-Coated Balloon Better for High-Risk In-Stent Restenosis

A drug-coated balloon beat conventional balloon angioplasty in treating high-risk patients with in-stent restenosis for outcomes of target lesion restenosis or failure, the AGENT IDE study has shown.

San franciscoUnited statesRobert yehDrug administrationBeth israel deaconess medical centerBoston scientificTranscatheter cardiovascular therapeuticsCardiovascular research institute dublinMater private hospitalIn stent restenosisIntimal hyperplasiaNtimal proliferationMooth muscle cell proliferationPercutaneous coronary interventionDrug eluting stentCoronary artery bypass graft

VIVA23 Presents Outcomes of Late-breaking Science from Abbott s LIFE-BTK, RESOLV FIH Study, and IN PACT AV Access Trial

The second round of late-breaking clinical trials were presented with results from three studies during the Vascular InterVentional Advances Conference, VIVA23, being held Oct. 30-Nov. 2 in Las Vegas, NV. Notably, results from Abbott’s LIFE-BTK randomized clinical trial (RCT) demonstrated that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.

San franciscoUnited statesNew zealandMarianne brodmannRobert looksteinRaghu kolluriWynn las vegasVascular interventional advances conferenceControlled trial evaluatingEluting resorbable scaffoldTranscatheter cardiovascular therapeuticsInfrapopliteal arteryNew england journalMonth resultsRutherford classificationTrial thrombosis predictors